Skip to content

Aisling Capital Management LP

Follow

13F filer, CIK 1766721, NEW YORK, NY

Aisling Capital Management LP reported $299,339,723 across 14 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-12. Its ten largest share positions make up 98.52% of the portfolio.

Accepted , ingested 13F-HR 0001766721-26-000004

Period
2026-09-30
Reported value
$299M
Holdings
14
Top 10 weight
98.52%
New
0
Sold out
0

Largest buys vs the previous quarter

SecurityShares changeApprox. value
CMPSadded+300,000$3.73M
VTVTadded+8,775$271K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
BBIOreduced-1,500,000-$98.7M
SRRKreduced-35,000-$1.69M
BCAXreduced-20,000-$372K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001766721-26-000004, largest first. % of portfolio is the value over $299,321,725, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
BBIOBRIDGEBIO PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 6,068,125 shares; 2025Q1: 6,068,125 shares; 2025Q2: 6,068,125 shares; 2025Q3: 6,089,611 shares; 2025Q4: 5,089,611 shares; 2026Q1: 5,089,611 shares; 2026Q2: 4,589,611 shares; 2026Q3: 3,089,611 shares 3,089,611$203M67.92%-1,500,000Timeline
SNDXSYNDAX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,025,000 shares; 2025Q1: 1,025,000 shares; 2025Q2: 1,316,806 shares; 2025Q3: 1,316,806 shares; 2025Q4: 1,316,806 shares; 2026Q1: 1,316,806 shares; 2026Q2: 1,316,806 shares; 2026Q3: 1,316,806 shares 1,316,806$24.8M8.27%0Timeline
CMPSCOMPASS PATHWAYS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 964,500 shares; 2025Q1: 1,198,418 shares; 2025Q2: 1,198,418 shares; 2025Q3: 1,198,418 shares; 2025Q4: 1,198,418 shares; 2026Q1: 1,432,336 shares; 2026Q2: 1,432,336 shares; 2026Q3: 1,732,336 shares 1,732,336$21.6M7.2%+300,000Timeline
GLUEMONTE ROSA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,472,331 shares; 2025Q1: 1,472,331 shares; 2025Q2: 1,472,331 shares; 2025Q3: 1,472,331 shares; 2025Q4: 1,472,331 shares; 2026Q1: 1,555,664 shares; 2026Q2: 1,555,664 shares; 2026Q3: 1,555,664 shares 1,555,664$18.6M6.2%0Timeline
BCAXBICARA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 568,919 shares; 2025Q1: 568,919 shares; 2025Q2: 568,919 shares; 2025Q3: 568,919 shares; 2025Q4: 568,919 shares; 2026Q1: 568,919 shares; 2026Q2: 568,919 shares; 2026Q3: 548,919 shares 548,919$10.2M3.41%-20,000Timeline
URGNUROGEN PHARMA LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 108,000 shares; 2026Q1: 108,000 shares; 2026Q2: 108,000 shares; 2026Q3: 108,000 shares 108,000$4.39M1.47%0Timeline
BBOTBRIDGEBIO ONCOLOGY THERAPEUTQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 564,625 shares; 2025Q4: 564,625 shares; 2026Q1: 1,018,018 shares; 2026Q2: 1,018,018 shares; 2026Q3: 1,018,018 shares 1,018,018$4.14M1.38%0Timeline
EPRXEUPRAXIA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 325,000 shares; 2026Q2: 325,000 shares; 2026Q3: 325,000 shares 325,000$2.96M0.99%0Timeline
BMEABIOMEA FUSION INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 798,757 shares; 2025Q1: 798,757 shares; 2025Q2: 2,048,757 shares; 2025Q3: 2,048,757 shares; 2025Q4: 2,048,757 shares; 2026Q1: 2,048,757 shares; 2026Q2: 2,048,757 shares; 2026Q3: 2,048,757 shares 2,048,757$2.74M0.92%0Timeline
ACRSACLARIS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 434,455 shares; 2025Q1: 434,455 shares; 2025Q2: 434,455 shares; 2025Q3: 434,455 shares; 2025Q4: 434,455 shares; 2026Q1: 434,455 shares; 2026Q2: 434,455 shares; 2026Q3: 434,455 shares 434,455$2.29M0.76%0Timeline
SRRKSCHOLAR ROCK HLDG CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 77,031 shares; 2025Q4: 77,031 shares; 2026Q1: 77,031 shares; 2026Q2: 77,031 shares; 2026Q3: 42,031 shares 42,031$2.03M0.68%-35,000Timeline
VTVTVTV THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 50,000 shares; 2026Q3: 58,775 shares 58,775$1.81M0.61%+8,775Timeline
MRKRMARKER THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 325,370 shares; 2025Q1: 325,370 shares; 2025Q2: 325,370 shares; 2025Q3: 325,370 shares; 2025Q4: 325,370 shares; 2026Q1: 325,370 shares; 2026Q2: 325,370 shares; 2026Q3: 325,370 shares 325,370$348K0.12%0Timeline
OKURONKURE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 88,607 shares; 2025Q1: 88,607 shares; 2025Q2: 88,607 shares; 2025Q3: 88,607 shares; 2025Q4: 88,607 shares; 2026Q1: 88,607 shares; 2026Q2: 88,607 shares; 2026Q3: 88,607 shares 88,607$241K0.08%0Timeline

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001766721-26-000004 base2026-11-12